Through the modulation of the IDO1/Kyn/AHR axis using ICA, Lactobacillus gallinarum has emerged as a potential adjunct to augment the effectiveness of anti-PD1 immunotherapy against CRC. Here, PDCD1 is linked to colorectal carcinoma.